Does Huntington's Start in the Gut?
Experiment #9 | June 29, 2026
Experiment Card
Can gut-targeted interventions intercept HD pathology before it reaches the brain — and does HD start as a systemic disease, not just a brain one?
The Unified Cascade (Experiments 7 → 9)
Three independent experiments now assemble into one coherent model. The gut sits at the very top: dysbiosis and a leaky gut barrier drive systemic inflammation and metabolic decline, which then trigger the lipid and epigenetic failures the earlier experiments identified.
Top Findings
HD is fundamentally a systemic disorder requiring intervention at the gut barrier and metabolic level, not just the CNS.
The Parkinson's model strongly validates that upstream metabolic failure and gut dysbiosis drive protein-propagation pathology — concepts highly conserved between PD and HD.
A multi-pronged approach: restore gut barrier/metabolism (butyrate, rifaximin), enhance proteostasis (CYP46A1), and provide symptomatic support (SPN excitability modulation).
Drug Candidates
| Candidate | Target | Score | Path |
|---|---|---|---|
| Sodium Butyrate (SCFA) | Gut barrier / HDAC inhibition | 90/100 | Used clinically; HD formulation needed |
| Rifaximin | Gut-specific antibiotic / dysbiosis | 88/100 | Approved, non-systemic — early-intervention candidate |
| AMPA PAMs / KATP modulators | SPN excitability | 75/100 | Symptomatic adjunct, not disease-modifying |
Novel Hypotheses Generated
Gut-derived metabolites directly impair mitochondrial function in striatal neurons via receptor signalling (e.g., TLRs).
How to test: Treat primary HD neuronal cultures with defined microbial supernatants (dysbiotic vs. eubiotic); measure mitochondrial membrane potential and ROS.
Targeting the gut-derived inflammatory signal (LPS/DAMPs) will reduce mHTT seeding efficiency in the CNS.
How to test: In mice, administer barrier enhancers (zinc, butyrate) before inducing HD pathology; quantify striatal mHTT spread.
Experiment #10: Gut → Mitochondria metabolic link
Quantify the direct metabolic link between gut dysbiosis and mitochondrial failure. Measure key metabolites (succinate, fumarate) and respiratory-chain activity in striatal neurons from HD models on a high-inflammatory/dysbiotic diet.
Experiment Trail
AI-generated for educational purposes only. Not clinical advice. Candidate drugs (butyrate, rifaximin) are discussed as research hypotheses about gut-brain biology, not treatment recommendations — do not self-medicate. Verify against primary literature. Data: PubMed (last 24 months). Model: Gemma 4, local inference. We are data scientists, not doctors.